SLAMF6 and neoplasm: In previous reports, however, EGFR signaling has been shown to modulate expression of immune-relevant molecules in tumor cells, including modulation of MHC class I signaling via STAT1/SHP2 pathways29 and transcriptional regulation of MHC class I.30 Our results showed a decrease rather than an increase on the expression of the NK-activating receptor natural killer group 2, member D (NKG2D) on the surface of NK cells from two different donors, following 16-h erlotinib treatment (Figure 5c).